# Matrisome Bio

Source: https://onco.cc/companies/matrisome-bio/  
OnCo record `matrisome-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Matrisome Bio is a Cambridge, Massachusetts start-up that aims treatments at the scaffolding around tumour cells, the extracellular matrix, rather than at the cells themselves. It is developing a radioactive medicine for lung cancer that has spread.

## Summary

Matrisome Bio, Inc., of Cambridge, Massachusetts, describes itself as a seed-stage start-up delivering payloads to disease-associated components of the extracellular matrix of tumours and metastases, using a toolbox of nanobody-based binders. In fiscal year 2026 the National Cancer Institute funded its SBIR project on an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancer (5R44CA298532-02, USD 1,013,647).

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: MATRISOME BIO, INC.
- HQ: Cambridge, MA
- Type: radiopharma
- Website: https://matrisomebio.com/

## Notes

- Read on matrisomebio.com and the NIH RePORTER record on 4 November 2026. The site names no product.

## Sources

- Official website: https://matrisomebio.com/
- NIH RePORTER: 5R44CA298532-02: https://reporter.nih.gov/project-details/11419641

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)

---
JSON: https://onco.cc/api/v1/entities/matrisome-bio.json